血管舒张性休克初始血压对血管紧张素II治疗反应的指数及其与临床结局的关联
本研究基于ATHOS-3试验数据,构建了血管紧张素II初始MAP反应指数(AIMRITE),定义为(第1小时MAP-基线MAP)/研究药物剂量。158例安慰剂患者中157例(99%)AIMRITE<0.90 mmHg/ng/kg/min,而163例血管紧张素II治疗患者中位AIMRITE为1.43 mmHg/ng/kg/min,其中97例(60%)为反应者、66例(40%)为抵抗者。AIMRITE每增加1.0单位,死亡风险降低16%(HR 0.84,95%CI 0.74-0.95,p=0.0062);反应者死亡风险约为抵抗者的一半(HR 0.50,95%CI 0.32-0.78,p=0.0026),也低于安慰剂组(HR 0.58,95%CI 0.40-0.86,p=0.0064);抵抗者与安慰剂组死亡风险相似(HR 1.17,95%CI 0.80-1.72,p=0.41)。该指数可能作为预后指标及早期识别最可能从血管紧张素II获益患者的工具。
要点
- AIMRITE定义为(第1小时MAP-基线MAP)/研究药物剂量,反应阈值≥0.90 mmHg/ng/kg/min。
- 血管紧张素II组中位AIMRITE为1.43 mmHg/ng/kg/min(IQR 0.35-2.83),60%为反应者(97/163)。
- AIMRITE每增加1.0单位,死亡风险降低16%(HR 0.84,95%CI 0.74-0.95,p=0.0062)。
- 反应者死亡风险约为抵抗者的一半(HR 0.50,95%CI 0.32-0.78,p=0.0026),也低于安慰剂组(HR 0.58,95%CI 0.40-0.86,p=0.0064)。
- 抵抗者与安慰剂组死亡风险相似(HR 1.17,95%CI 0.80-1.72,p=0.41)。
适用人群与场景
- 儿茶酚胺难治性血管舒张性休克患者,数据来自ATHOS-3试验。
诊断标准与关键阈值
- AIMRITE =(第1小时MAP-基线MAP)/研究药物剂量。
- 反应者定义为AIMRITE ≥ 0.90 mmHg/ng/kg/min,抵抗者定义为AIMRITE < 0.90 mmHg/ng/kg/min。
研究设计与关键结果
- 研究类型:基于ATHOS-3试验数据的分析;样本量:安慰剂组158例,血管紧张素II组163例。
- 安慰剂组157例(99%)AIMRITE<0.90 mmHg/ng/kg/min(中位0.02;IQR -0.03-0.10);血管紧张素II组中位AIMRITE 1.43 mmHg/ng/kg/min(IQR 0.35-2.83)。
- 血管紧张素II组中反应者97例(60%),中位AIMRITE 2.55(IQR 1.66-4.12);抵抗者66例(40%),中位AIMRITE 0.24(IQR 0.10-0.52)。
- 主要终点28天死亡:AIMRITE每增加1.0单位,HR 0.84(95%CI 0.74-0.95,p=0.0062);反应者vs抵抗者HR 0.50(95%CI 0.32-0.78,p=0.0026);反应者vs安慰剂HR 0.58(95%CI 0.40-0.86,p=0.0064);抵抗者vs安慰剂HR 1.17(95%CI 0.80-1.72,p=0.41)。
- 反应者较抵抗者基线肾素和肾素/血管紧张素II比值更低,但第3小时两者下降幅度更大。
- 按基线肾素水平分层,死亡最高见于高肾素的安慰剂患者(69%)和低肾素的血管紧张素II抵抗患者(61%)。
证据类型、等级与局限
- 证据类型:基于随机对照试验ATHOS-3数据的分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为AIMRITE可能作为预后指标及早期识别最可能从血管紧张素II获益患者的工具。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: No standardized index exists to assess cardiovascular responsiveness to angiotensin-II. We hypothesized that a standardized index of initial blood pressure response to angiotensin-II treatment would be associated with clinical outcomes.
METHODS: Using data from the Angiotensin Therapy for High Output Shock (ATHOS-3) trial, we developed an Angiotensin-II Initial MAP Response Index of Treatment Effect (AIMRITE) defined as (MAP at hr1 - MAP at baseline)/study drug dose. We assessed AIMRITE continuously and, based on observed distributions, we additionally categorized patients as "responsive" or "resistant", with responsiveness defined by an AIMRITE ≥ 0.90 mmHg/ng/kg/min. The primary clinical outcome was 28-day mortality. Secondary outcomes included days alive and vasopressor- or ventilator- or renal replacement therapy-free at day-7. Biological outcomes included baseline renin, angiotensin-II, and renin/angiotensin-II ratio, and their change at hr3.
RESULTS: Of 158 placebo patients, as expected, 157 (99%) had AIMRITE < 0.90 mmHg/ng/kg/min (median AIMRITE 0.02; IQR - 0.03-0.10). In contrast, 163 patients assigned to angiotensin-II had a median AIMRITE of 1.43 mmHg/ng/kg/min (IQR 0.35-2.83). Of these, 97 (60%) were responsive (median AIMRITE 2.55; IQR 1.66-4.12) and 66 (40%) were resistant (median AIMRITE 0.24; IQR 0.10-0.52). Each 1.0-unit increase in AIMRITE was associated with a 16% lower hazard of death (HR: 0.84 per-mmHg/ng/kg/min [95% CI 0.74-0.95], p = 0.0062). Responsive patients had half the mortality hazard than resistant patients (HR: 0.50 [95% CI 0.32-0.78], p = 0.0026) and placebo patients (HR 0.58 [95% CI 0.40-0.86], p = 0.0064). Resistant patients had a similar mortality hazard to placebo (HR 1.17 [95% CI 0.80-1.72], p = 0.41). Compared to resistant patients, responsive patients had lower baseline renin and renin/angiotensin-II ratio, but a greater decrease in both at hr3. When stratified by baseline renin level, mortality was highest in placebo patients with high renin (69%) and angiotensin-II resistant patients with low renin (61%).
CONCLUSIONS: Among patients with catecholamine-refractory vasodilatory shock treated with angiotensin-II, the AIMRITE was associated with mortality at day-28. Responsive angiotensin-II patients had higher survival versus both angiotensin-II resistant patients and those treated with placebo plus standard vasopressors. This index may serve as a prognostic indicator and early identifier of patients most likely to benefit from angiotensin-II.
参考来源
- Leisman DE, Wieruszewski PM, Busse LW, et al. An index of the initial blood pressure response to angiotensin II treatment and its association with clinical outcomes in vasodilatory shock. Crit Care. 2025. PMID: 39972379. doi:10.1186/s13054-025-05311-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。